A Phase I/II Study of Vorinostat (Zolinza) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer

Trial Profile

A Phase I/II Study of Vorinostat (Zolinza) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Vorinostat (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 May 2016 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Cancer.
    • 12 May 2016 Primary endpoint has not been met. (Phase II - 6-month progression-free survival (PFS) rate), as per results published in the British Journal of Cancer.
    • 12 May 2016 Results of phase II portion and biomarker analysis published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top